Patents by Inventor Robert F. Halenbeck

Robert F. Halenbeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulation, Solubilization, Purification, and Refolding of Tissue Factor Pathway Inhibitor
    Publication number: 20080281084
    Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.
    Type: Application
    Filed: April 5, 2007
    Publication date: November 13, 2008
    Applicants: Novartis Vaccines and Diagnostics, Inc., G. D. Searle LLC
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Raisharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor
    Patent number: 7226757
    Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: June 5, 2007
    Assignees: G.D. Searle LLC, Novartis Vaccines and Diagnostics, Inc.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Raisharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Protein associated with cell stress response
    Patent number: 7186530
    Abstract: A stress-phosphorylated endoplasmic reticulum protein, Nogo B, is provided. The protein is hyperphosphorylated as a result of exposure of cells to stress. Two transcripts of Nogo B are identified in human tissues, and the longer transcript is predominant in human brain tumor samples.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: March 6, 2007
    Assignee: Chiron Corporation
    Inventors: Dong Wei, Robert F. Halenbeck, Lewis T. Williams
  • Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor
    Patent number: 7022672
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: April 4, 2006
    Assignees: Chiron Corporation, G. D. Searle, LLC
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rejsharan K. Bana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Recombinant PR-3 and assays employing the same
    Patent number: 6599706
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Jan Tuttleman, Carl Perez, David A. Jewell, Kirston E. Koths
  • Recombinant PR-3 and compositions thereof
    Patent number: 6586222
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • Method of solubilizing, purifying, and refolding protein
    Patent number: 6323326
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: November 27, 2001
    Assignees: Chiron Corporation, G. D. Searle & Co.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hoba, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • Method of solubilizing, purifying, and refolding protein
    Patent number: 6319896
    Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: November 20, 2001
    Assignees: Chiron Corporation, G.D. Searle & Co.
    Inventors: Glenn J. Dorin, Bo H. Arve, Gregory L. Pattison, Robert F. Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan K. Rana, Maninder S. Hora, Hassan Madani, Michael Tsang, Mark E. Gustafson, Gary S. Bild, Gary V. Johnson
  • DNA encoding N?2 CSF-1 (short form) and carboxy truncated fragment thereof
    Patent number: 6204020
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both “long” and “short” forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: March 20, 2001
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments thereof
    Patent number: 6156300
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: December 5, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding NV2 (long form) and carboxy truncated fragments thereof
    Patent number: 6146851
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: November 14, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof
    Patent number: 6117422
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 12, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof
    Patent number: 6103224
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 15, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Secreted mac-2-binding glycoprotein
    Patent number: 6069127
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approtely 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 30, 2000
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • Compositions for the inhibition of TNF hormone formation and uses thereof
    Patent number: 5998378
    Abstract: Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from a decrease in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors such as 26 kDProTNF, and methods for identifying compounds having the desired inhibitory activity are provided.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: December 7, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl Perez, Robert F. Halenbeck, David A. Jewell, Kirston E. Koths
  • Nucleic acid encoding secreted Mac-2 binding glycoprotein
    Patent number: 5965382
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: October 12, 1999
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • Assay method for screening for inhibitors of proTNF conversion
    Patent number: 5843693
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF.alpha.. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF.alpha. to its mature active form.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: December 1, 1998
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Carl Perez, David A. Jewell, Kirston E. Koths
  • Secreted Mac-2-binding glycoprotein
    Patent number: 5736340
    Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for reagents that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system, and for monitoring the concentration of the glycoprotein in human milk.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 7, 1998
    Assignee: Chiron Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
  • DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants
    Patent number: 5681719
    Abstract: DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: October 28, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N- 3 deletion mutants of the long form of CSF-1
    Patent number: 5672343
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 30, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths